HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Allergy & Immunology
Meta-analysis
EMA-approved biologics and JAK inhibitors show meaningful short-term EASI-75 responses in moderate-to-severe atopic dermatitis
Newer Eczema Drugs Clear Skin for Many, But Comparisons Are Tricky
This systematic review narratively synthesized randomized trials of EMA-approved systemic therapies for moderate-to-severe atopic dermatitis…
Seven eczema drugs helped 18% to 73% of adults reach clearer skin in 12 to 16 weeks. But trials varied too much to say which works best.
Frontiers
Oct 31, 2026
Drug Pipeline
Meta-analysis
Abrocitinib significantly improves Investigator Global Assessment response and pruritus in moderate-to-severe atopic dermatitis
Abrocitinib improves skin severity and itching in eczema patients
This meta-analysis of randomized controlled trials evaluated abrocitinib for patients with moderate-to-severe atopic dermatitis. The analysi…
A new analysis shows abrocitinib helps people with moderate to severe atopic dermatitis reduce skin inflammation and experience less intense…
Frontiers
Aug 24, 2026
Dermatology
Sys. Review
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
Jul 1, 2026